Project Grant R21AI196189
Award Date 8/18/26
Completion Date 7/31/28
Dollars Obligated $265K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $191,268 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the epigenetic architecture of autoimmune risk loci, with focus on multiple sclerosis and type 1 diabetes. The award funds research into noncoding genetic variants and their role in autoimmune disease susceptibility. The project uses long-read chromatin fiber sequencing techniques...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $497,779 on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the FN-14 receptor in TNF-induced inflammation and tissue destruction, with performance through January 31, 2031. The research addresses the partial ineffectiveness of TNF-alpha inhibitors in treating rheumatoid arthritis and related inflammatory diseases in over 40...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $296,414 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate effector-triggered inflammasome activation in rotavirus host defense and viral pathogenesis. The research addresses rotavirus as the primary cause of severe dehydrating diarrhea in children under age five, responsible for approximately two million hospitalizations and over 200,000 deaths...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $804,183 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design bifunctional chimeric proteins that redirect immune responses against antibiotic-resistant bacterial pathogens. The project applies deep learning-enabled protein design to create bacterial targeting chimeras (BacTACs) that simultaneously bind surface proteins on antibiotic-resistant bacteria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $2.719 million on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define a unifying framework for how type 2 immune responses are initiated, maintained, and recalled across barrier tissues. The award funds four interdependent research projects addressing distinct tissue contexts. Project 1 defines a neuro-epithelial-immune circuit in the small intestine...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $485,375 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of complement-mediated clearance of extracellular mitochondria released by dying neutrophils. The research explores how neutrophils proteolytically activate complement C3 and deposit it on mitochondria as an opsonin to facilitate their clearance by myeloid cells, thereby...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $144,196 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the functional role and biophysical characterization of the disordered N-terminal domain from the Borna disease virus phosphoprotein. The project, led by Principal Investigator Madison A. Stringer, combines biochemical and biophysical techniques to characterize the N-terminal...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $777,498 to the University of Washington on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural basis of parasteric inhibition mechanisms targeting bacterial adhesins, specifically the fimbrial lectin FimH of uropathogenic E. coli. The project characterizes how monoclonal antibodies and de novo-designed miniproteins...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $414,305 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate influenza neuraminidase structure and dynamics with emphasis on how stalk variation impacts enzymatic function and immune recognition. The research addresses structural variation in influenza neuraminidase, a sialidase that cleaves sialic acid from host glycoproteins and glycolipids,...